Data from Pharmawand - Curated by EPG Health - Date added 14 November 2017
Theravance Biopharma, Inc. and Mylan N.V. announced the submission of a New Drug Application (NDA) to the FDA for revefenacin (TD 4208), an investigational long-acting muscarinic antagonist (LAMA) as a once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD).
The NDA is supported by the companies' Phase III program for revefenacin, which consisted of two replicate pivotal Phase III efficacy studies and a 12-month, open-label, active comparator safety study.
Comment:This submission represents a key step in efforts to bring the first once-daily nebulized LAMA to the COPD patient community. While a significant number of COPD patients require or prefer nebulized therapy, these same patients currently have no access to a nebulized LAMA, broadly considered the cornerstone of COPD maintenance therapy.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Cystic Fibrosis Knowledge Centre
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.